SARomics Biostructures is Biotechnology in Sweden that focus on drug design business. Founded in 2006. They cover business area such as operator, an integrate drug discovery platform, expertise, structure-base drug design, structural biology service, testing, analysis, validation, biosimilar, fragment screening, fragment-base drug design, computational chemistry, silico, client, Asia, Europe, North America, Scandinavia, their drug discovery objective.
2006
( 18 years old in 2024 )
Drug Design
-
Medicon Village
223 81 Lund
Sweden
Private
operatoran integrate drug discovery platformexpertisestructure-base drug designstructural biology servicetestinganalysisvalidationbiosimilarfragment screeningfragment-base drug designcomputational chemistrysilicoclientAsiaEuropeNorth AmericaScandinaviatheir drug discovery objective
* We use standard office opening hours in near SARomics Biostructures's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
SARomics Biostructures is Biotechnology business from Sweden that founded in 2006 (18 years old in 2024), SARomics Biostructures business is focusing on Drug Design.
SARomics Biostructures headquarter office and corporate office address is located in Medicon Village 223 81 Lund Sweden.
SARomics Biostructures was founded in Sweden.
In 2024, SARomics Biostructures is currently focus on drug design sector.
Above is snippet of Google Trends for "drug design" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with SARomics Biostructures, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.